| 摘要: |
| 目的:比较集中带量采购(以下简称集采)政策实施前后注射用头孢曲松钠在儿科患者中治疗效果的差异,为临床合理 用药提供参考。 方法:采用随机抽样方法抽取我院 2021 年 3-5 月(集采前)和 2022 年 3-5 月(集采后)使用注射用头孢曲松钠 的患儿资料,通过方差分析、药物经济学最小成本法(cost-minimization analysis,CMA)及安全性监测对比分析两组患儿的治疗效 果、不良反应发生情况及医疗费用差异。 结果:共纳入 369 例患儿(集采前 207 例,集采后 162 例)。 有效性方面,集采前后临床 疗效、治疗时间、7 d 内出院率、炎症指标转归、病原菌清除率、治疗失败率比较差异均无统计学意义(P>0. 05)。 安全性方面,集 采前后不良反应总体发生率比较差异无统计学意义(P = 0. 257)。 经济性方面,集采后注射用头孢曲松钠药品费用及住院总费 用均低于集采前(P<0. 05),CMA 分析与敏感性分析结果一致。 结论:注射用头孢曲松钠集采前后在儿科患者中有效性和安全 性比较差异无统计学意义,集采后更具经济性。 |
| 关键词: 儿童 注射用头孢曲松钠 集中带量采购 有效性评价 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2025.09.009 |
|
| 基金项目:陕西省保健学会药学服务科研基金项目,编号 KY-2023-01-YX-023。 |
|
| Comprehensive Evaluation of Ceftriaxone Sodium for Injection Based on the Real-World Pediatric Clinical Practice Before and After Centralized Drug Volume-Based Procurement |
| Yang Tianjiang, Zhao Kai, Wei Zeyang, Liu Zhenguo |
| (Northwest Women’s and Children’s Hospital, Xi’an 710061, China) |
| Abstract: |
| Objective: To compare the differences in the therapeutic effects of ceftriaxone sodium for injection in children before and after implementation of the centralized drug volume-based procurement policy (hereinafter referred to as “centralized procurement”), and to provide reference for the rational drug use in clinic. Methods: Random sampling method was used to extract the data of children with ceftriaxone sodium for injection in our hospital from Mar. to May 2021 ( before centralized procurement) and from Mar. to May 2022 (after centralized procurement). Differences in therapeutic effects, occurrence of adverse drug reactions and medical expenses between two groups were compared and analyzed through analysis of variance, pharmacoeconomic cost-minimization analysis (CMA) and safety monitoring. Results: A total of 369 children were enrolled (with 207 cases before centralized procurement and 162 cases after centralized procurement). In terms of effectiveness, there were no statistically significant differences in clinical efficacy, treatment duration, seven-day discharge rate, outcome of infection indicators, pathogen clearance rate, and treatment failure rate before and after implementation of centralized procurement policy (P>0. 05). In terms of safety, there was no statistically significant difference in the overall incidence of adverse drug reactions before and after implementation of centralized procurement policy (P = 0. 257). In terms of economy, the cost of ceftriaxone sodium for injection and total hospitalization cost after implementation of centralized procurement policy were both lower than those before implementation of centralized procurement policy ( P < 0. 05). The results of CMA analysis and sensitivity analysis were consistent. Conclusion: There is no statistically significant difference in the efficacy and safety of ceftriaxone sodium for injection in children before and after implementation of centralized procurement policy. Moreover, the centralized procurement policy results in greater economic benefits. |
| Key words: children ceftriaxone sodium for injection centralized drug volume-based procurement policy effectiveness evaluation |
